Journal
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
Volume 130, Issue 3, Pages 419-424Publisher
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/yakushi.130.419
Keywords
methazolamide; calcium phosphate nanoparticle; ocular delivery system; sustained release
Categories
Funding
- Nanjing Carrier Nanobiotech Company
Ask authors/readers for more resources
A new system for the local delivery of methazolamide to the eye has been developed based on calcium phosphate (CaP) nanoparticles. The methazolamide loaded CaP nanoparticles were prepared through the formation of an inorganic core of CaP and further adsorption of the methazolamide. The maximum loading of methazolamide studied using UV-vis spectrophotometry was about 0.2% (w/w). The drug-loaded particles had a negative surface charge at about - 30 mV while their mean particle diameter was estimated to be 256.4 nm. In vitro release studies demonstrated diffusion-controlled release of methazolamide from the CaP nanoparticles over a period of 4 h. In vivo studies indicated that the intraocular pressure (IOP) -lowering effect of the inorganic nanoparticle eye drops lasted for 18 h, which was significantly better than the effect of 1% brinzolamide eye drops (6 h). Physical stability studies indicated that the preparation was stable for 6 months at 40 degrees C. These findings suggested that methazolamide bound to CaP nanoparticles might be useful in the local treatment of glaucoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available